<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952467</url>
  </required_header>
  <id_info>
    <org_study_id>XPF-008-103</org_study_id>
    <secondary_id>2021-000735-32</secondary_id>
    <nct_id>NCT04952467</nct_id>
  </id_info>
  <brief_title>Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101</brief_title>
  <official_title>An Open Label, Single-dose, Single-period Study to Assess the Pharmacokinetics, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-XEN1101 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xenon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the mass balance recovery and metabolite profile, and will identify&#xD;
      metabolite structures following a single oral dose of 14C-XEN1101 in healthy adult male&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity excreted in urine and faeces following oral administration of XEN1101</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>Cumulative amount of total radioactivity excreted in urine and feces combined (CumAe(total)) and expressed as a % of the radioactive dose administered (Cum%Ae(total)) following oral administration of 14C-XEN1101</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>14C Metabolite profiling in of plasma, urine and feces</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>Chemical structure of each metabolite classified as &gt;10% (by AUC) of total radioactivity in plasma and &gt;10% dose excreted in urine and faeces following oral administration of XEN1101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) data for 14C-XEN1101; Tmax</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>Time of maximum observed concentration for XEN1101 and metabolites in plasma and for total radioactivity in plasma and whole blood following oral administration of 14C-XEN1101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK data for 14C-XEN1101; Cmax</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>Maximum observed concentration for XEN1101 and metabolites in plasma and for total radioactivity in plasma and whole blood following oral administration of 14C-XEN1101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK data for 14C-XEN1101; T1/2</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>Terminal elimination half-life for XEN1101 and metabolites in plasma and for total radioactivity in plasma and whole blood following oral administration of 14C-XEN1101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mass balance data for 14C-XEN1101 in urine</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>CumAe(urine)expressed as a percentage of the radioactive dose administered (Cum%Ae(urine))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mass balance data for 14C-XEN1101 in feces</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>CumAe(feces) expressed as a percentage of the radioactive dose administered Cum%Ae(feces)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma whole blood concentration ratios for total radioactivity</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
    <description>Evaluation of whole blood:plasma concentration ratios for total radioactivity for corresponding time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations</measure>
    <time_frame>From Screening up to Day 57 post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Drug: (14C)-XEN1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive oral 14C-XEN1101 under fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-XEN1101</intervention_name>
    <description>Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101</description>
    <arm_group_label>Drug: (14C)-XEN1101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2&#xD;
&#xD;
          -  Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Adhere to the specified contraception requirements&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any investigational medicinal product (IMP) in a clinical&#xD;
             research study within 90 days&#xD;
&#xD;
          -  Evidence of any current infection or an infection within 14 days before study drug&#xD;
             administration&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Subjects with pregnant or lactating partners&#xD;
&#xD;
          -  Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5&#xD;
             millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. No&#xD;
             occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017,&#xD;
             shall participate in the study&#xD;
&#xD;
          -  Participation in a clinical trial involving administration of radiolabelled&#xD;
             compound(s) within 180 days of the planned dosing date of this study&#xD;
&#xD;
          -  Clinically significant abnormal clinical chemistry, haematology, coagulation or&#xD;
             urinalysis. Subjects with Gilbert's Syndrome will be excluded.&#xD;
&#xD;
          -  Confirmed positive drugs of abuse test result&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) antibody results&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, dermatological,&#xD;
             chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder&#xD;
&#xD;
          -  Donation of blood or plasma within the previous 3 months or loss of greater than 400&#xD;
             mL of blood&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Xenon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xenon Pharmaceuticals Inc.</last_name>
    <phone>1-604-484-3300</phone>
    <email>XenonCares@xenon-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XEN1101</keyword>
  <keyword>Mass Balance</keyword>
  <keyword>Phase 1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

